Plasma Treatment Trials Expanded by U.S. to Show Safety, Benefit

Trials of a human blood-based Covid-19 treatment that was granted emergency authorization by the U.S. will be expanded to prove whether it’s safe and effective.

Two human studies of convalescent plasma, a component of blood taken from recovered coronavirus patients, will enroll more patient at hospitals and clinics across the country, with $48 million from the Operation Warp Speed program to accelerate drug and vaccine development.